Novartis submits BLA for vaccine


Novartis (NVS) submits its BLA to the FDA for its Breakthrough Therapy-designated meningitis B vaccine Bexsero (Multicomponent Meningococcal Group B Vaccine [recombinant, absorbed]). The vaccine helps protect adolescents and young adults from ages 10 - 25 against invasive meningococcal disease caused by serogroup B (meningitis B).

Bexsero is the first broad coverage vaccine to help protect against meningitis. It provides protection against the five main serogroups (A, B, C, W-135, Y) of meningocccal bacteria. Prior to Bexsero, serogroup B was unaddressed.

It is already approved in 34 countries including the EU, Canada and Australia. Since the product was launched in 2013, over 500K doses have been distributed.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs